Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.21.2
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2019
Jan. 31, 2018
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Revenue recognized         $ 5,162,000 $ 3,188,000 $ 9,989,000 $ 5,566,000  
Deferred revenue         16,974,000   16,974,000   $ 22,086,000
Deferred revenue, net of current portion         4,851,000   4,851,000   9,877,000
Global Blood Therapeutics                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue         14,257,000   14,257,000   16,721,000
Global Blood Therapeutics | Collaboration Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Initial period of research term 3 years                
Additional extension period for research term upon mutual agreement 1 year                
Upfront payment receivable $ 20,000,000.0                
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000.0                
Agreement termination, prior written notice if notice delivered during the research term 9 months                
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days                
Total transaction price $ 60,000,000.0           60,000,000.0    
Upfront non-refundable and non-creditable payment 20,000,000.0                
Reimbursable costs $ 40,000,000.0                
Change in total transaction price             0    
Revenue recognized         3,300,000 2,500,000 7,400,000 4,700,000  
Deferred revenue         14,300,000   14,300,000    
Deferred revenue, short-term         9,600,000   9,600,000    
Deferred revenue, net of current portion         4,700,000   4,700,000    
Global Blood Therapeutics | Collaboration Agreement | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Period of extension of initial research term 2 years                
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000.0                
Incyte                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Revenue recognized         1,900,000 $ 700,000 2,600,000 $ 900,000  
Deferred revenue         2,717,000   2,717,000   $ 5,365,000
Deferred revenue, short-term         2,600,000   2,600,000    
Deferred revenue, net of current portion         $ 100,000   100,000    
Incyte | Stock Purchase Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Aggregate purchase price       $ 10,000,000.0          
Shares issued       793,021          
Share price (in dollars per share)       $ 12.61          
Premium to volume-weighted sale price of shares (as a percent)       30.00%          
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares       15 days          
Incyte | Collaboration Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total transaction price   $ 12,300,000 $ 12,800,000       12,800,000    
Upfront non-refundable and non-creditable payment             2,500,000    
Up-front consideration       $ 10,000,000.0          
Up-front consideration, cash       2,500,000          
Up-front consideration, pre-paid research funding       $ 7,500,000          
Prepaid research amount             7,500,000    
Premium paid on equity investment             2,300,000    
Collaboration agreement additional consideration incurred             $ 500,000